Sprycel is a targeted drug used to treat some types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with a positive Philadelphia chromosome (Ph+ ALL). Sprycel is used to treat chronic myeloid leukemia (CML) in adults and kids 12 months and older. Acute lymphoblastic leukemia (ALL), commonly known as Ph+ ALL, is a specific type of ALL that affects both adults and children 12 months of age and older. A malignancy of developing white blood cells, leukemia develops in the bone marrow. Normally, as these white blood cells develop, they enter the bloodstream where they combat illness and support the immune system of the body.
The Global Sprycel Market size is estimated to be valued at US$ 5.68 billion in 2023 and is projected to reach US$ 8.26 billion by 2030, growing at a CAGR of 5.5% during the forecast period (2023-2030).
Ask Us to Get Your Sample Copy Of The Report, Covering TOC and Regional Analysis @
https://www.coherentmarketinsights.com/insight/request-sample/6058
Top Companies Associated with the Sprycel Market
- Bristol-Myers Squibb (BMS)
- Novartis
- Teva Pharmaceutical Industries
- Mylan
- Accord Healthcare
- Sun Pharma
- Reddy’s Laboratories
- Aurobindo Pharma
Sprycel Market Drivers
CML and Ph+ ALL incidence: CML and Ph+ ALL have been on the rise all around the world. The need for potent medications like Sprycel increases as more patients are given these diagnoses.
Efficacy and safety profile:Sprycel has shown great success in treating CML and Ph+ ALL, which has resulted in favorable clinical results for many patients. Many medical professionals and patients choose it because of its safety profile when administered properly.
Targeted therapy:Tyrosine kinase inhibitors (TKIs), which include Sprycel, are a group of medications that specifically target molecules involved in the development and growth of cancer cells. Due to their capacity to prevent the growth of cancer cells while causing the least amount of harm to healthy cells, targeted medicines like Sprycel are becoming more and more crucial in the fight against cancer.
Resistance to other therapies: Some CML and Ph+ ALL patients may become resistant to or intolerant to imatinib or other medications. Sprycel is frequently utilized as a follow-up or second-line therapy in such circumstances, which propels market demand.
Recent Developments
- In 2021, the FDA approved asciminib (Sprout), a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, for the treatment of chronic-phase CML patients who had undergone two lines of prior therapy and had failed, as well as for patients with the T315I mutation.
- Patients with chronic-phase CML who are resistant to or intolerant to imatinib or other tyrosine kinase inhibitors may be treated with ponatinib (Iclusig), a second-generation tyrosine kinase inhibitor.
- Bosutinib (Bosulif), a second-generation tyrosine kinase inhibitor, was authorized for use in 2012 to treat CML patients who are imatinib-resistant or imatinib-intolerant.
Sprycel Market Report Coverage
| The market size value in 2023 |
Purchase This Premium Report and Get Up To 25% OFF @
https://www.coherentmarketinsights.com/insight/buy-now/6058
Market Dynamics:
During the projected period, the worldwide sprycel market is anticipated to increase as a result of factors such as expanding indications, the prevalence of targeted indications rising, the efficacy and safety profile improving, and creative improvements.
However, during the course of the projection period, the worldwide sprycel market is likely to have growth constraints due to intense competition, patent expiration, regulatory challenges, negative effects, and pricing and reimbursement issues.
Detailed Segmentation:
- Global Sprycel Market By Demographic:
- Age
- Gender
- Income
- Global Sprycel Market By Psychographic:
- Lifestyle
- Attitudes
- Global Sprycel Market By Behavioral:
- Usage Rate
- Compliance
- Treatment History
- Global Sprycel Market By Medical:
- Indication
- Disease Stage
Sprycel Market Trends
Increasing emphasis on targeted therapies: Cancer treatment is increasingly relying on targeted treatments like Sprycel, which selectively disrupt the molecular targets implicated in cancer growth. The need for targeted medicines, which offer better efficacy and fewer side effects than conventional chemotherapy, is rising as a result of the push toward personalized medicine and precision oncology.
Evolving treatment guidelines: On the basis of newly available data and clinical studies, treatment recommendations for CML and Ph+ ALL are frequently updated. These recommendations affect the use and uptake of Sprycel as well as the treatment choices made by medical providers. To coordinate the use of Sprycel with suggested treatment procedures, it’s crucial to stay current with the guidelines as they change.
Competitive landscape:Other tyrosine kinase inhibitors (TKIs) for CML and Ph+ ALL compete with Sprycel for patients. In addition to more recent TKIs like ponatinib (Iclusig) and bosutinib (Bosulif), rival medications like imatinib (Gleevec) and nilotinib (Tasigna) are well-established choices. Market share and pricing dynamics may be influenced by rivalry among various therapies.
Table of Contents with Major Points:
Executive Summary
- Introduction
- Key Findings
- Recommendations
- Definitions and Assumptions
Executive Summary
Market Overview
- Definition of Sprycel Market
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Trends and Developments
Key Insights
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global Sprycel Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
Conclusion
Appendix
- Data Sources
- Abbreviations
- Disclaimer
TOC Continued…!
Ask For Discount Before Purchasing This Business Report @
https://www.coherentmarketinsights.com/insight/request-discount/6058
Why Choose Coherent Market Insights?
☛ Identified business opportunities – Our market research report can be used to analyze potential markets and new products. It can give information about customer needs, preferences, and attitudes. Also, it compare products and services.
☛ A clear understanding of your customers – A market report gives company’s marketing department an in-depth picture about customers’ needs and wants. This knowledge can be used to improve products, prices, and advertising.
☛ Clear data-driven insights – Our Market research encompasses a wide range of activities, from determining market size and segment to forecasting demand, and from identifying competitors to monitoring pricing. All of these are quantified and measurable which means that gives you a clear path for building unique decisions based on numbers.
Explore More Related Insights:
Cannabidiol consumer health market
Mucopolysaccharidosis treatment market
Immune health supplements market
Asia pacific facial care market
North america companion animal drugs market
Colombia wound care biologics market
Animal placental protein market
Uae heart failure drugs treatment market
Hemoglobinopathy treatment drugs market
North america companion animal drugs market
Allergic asthma therapeutics market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter